Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with CFTR Mutations Causing Pancreatic Insufficiency

Hepatobiliary involvement is a hallmark in cystic fibrosis (CF), as the causative CF Transmembrane Conductance Regulator (CFTR) defect is expressed in the biliary tree. However, bile acid (BA) compositions in regard to pancreatic insufficiency, which is present at an early stage in about 85% of CF patients, have not been satisfactorily understood. We assess the pattern of serum BAs in people with CF (pwCF) without CFTR modulator therapy in regard to pancreatic insufficiency and the CFTR genotype. In 47 pwCF, 10 free and 12 taurine- and glycine-conjugated BAs in serum were prospectively assessed. Findings were related to genotype, pancreatic insufficiency prevalence (PIP)-score, and hepatic involvement indicated by serum liver enzymes, as well as clinical and ultrasound criteria for CF-related liver disease. Serum concentrations of total primary BAs and free cholic acid (CA) were significantly higher in pwCF with higher PIP-scores (p = 0.025, p = 0.009, respectively). Higher total BAs were seen in pwCF with PIP-scores ≥0.88 (p = 0.033) and with pancreatic insufficiency (p = 0.034). Free CA was higher in patients with CF-related liver involvement without cirrhosis, compared to pwCF without liver disease (2.3-fold, p = 0.036). pwCF with severe CFTR genotypes, as assessed by the PIP-score, reveals more toxic BA compositions in serum. Subsequent studies assessing changes in BA homeostasis during new highly effective CFTR-modulating therapies are of high interest.

[1]  James C Poland,et al.  Bile Acids, Their Receptors, and the Gut Microbiota. , 2021, Physiology.

[2]  A. Szwengiel,et al.  Serum bile acids in cystic fibrosis patients-glycodeoxycholic acid as a potential marker of liver disease. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  S. Yagi,et al.  Liver Regeneration after Hepatectomy and Partial Liver Transplantation , 2020, International journal of molecular sciences.

[4]  H. Verkade,et al.  Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  H. Verkade,et al.  Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[6]  R. Houwen,et al.  IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  H. Corvol,et al.  Modifier genes in cystic fibrosis-related liver disease , 2019, Current opinion in gastroenterology.

[8]  H. Jaeschke,et al.  Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis , 2018, Journal of clinical and translational research.

[9]  J. Mainz,et al.  Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients , 2017, Scientific Reports.

[10]  H. Verkade,et al.  Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease , 2017, Current opinion in pulmonary medicine.

[11]  M. Trauner,et al.  Cystic Fibrosis–related Liver Disease: Research Challenges and Future Perspectives , 2017, Journal of pediatric gastroenterology and nutrition.

[12]  B. Koletzko,et al.  Serum Phospholipid Fatty Acid Composition in Cystic Fibrosis Patients with and without Liver Cirrhosis , 2017, Annals of Nutrition and Metabolism.

[13]  W. Buurman,et al.  Evidence for a Cystic Fibrosis Enteropathy , 2015, PloS one.

[14]  W. Cichy,et al.  Liver disease in cystic fibrosis , 2014, Przeglad gastroenterologiczny.

[15]  H. Baba,et al.  External biliary drainage and liver regeneration after major hepatectomy , 2012, The British journal of surgery.

[16]  B. Strandvik,et al.  Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[17]  J. Chiang,et al.  Bile acids: regulation of synthesis , 2009, Journal of Lipid Research.

[18]  M. Corey,et al.  Genetic modifiers of liver disease in cystic fibrosis. , 2009, JAMA.

[19]  Colin Hill,et al.  Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome , 2008, Proceedings of the National Academy of Sciences.

[20]  Dae-Joong Kang,et al.  Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005. , 2006, Journal of Lipid Research.

[21]  F. Ratjen Restoring airway surface liquid in cystic fibrosis. , 2006, The New England journal of medicine.

[22]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[23]  K. Setchell,et al.  Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis , 2004, Hepatology.

[24]  L. Agellon,et al.  Differential modulation of cellular death and survival pathways by conjugated bile acids , 2001, BMC Biochemistry.

[25]  D. Savage,et al.  Bile Salt Hydrolase Activity and Resistance to Toxicity of Conjugated Bile Salts Are Unrelated Properties in Lactobacilli , 2001, Applied and Environmental Microbiology.

[26]  P. Oliveira,et al.  Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  A. Hofmann,et al.  The continuing importance of bile acids in liver and intestinal disease. , 1999, Archives of internal medicine.

[28]  C. Springer,et al.  Clinical and Genetic Risk Factors for Cystic Fibrosis-related Liver Disease , 1999, Pediatrics.

[29]  G. Svegliati-Baroni,et al.  Carrier-mediated transport of conjugated bile acids across the basolateral membrane of biliary epithelial cells. , 1997, The American journal of physiology.

[30]  B. Strandvik,et al.  Bile acid kinetics and biliary lipid composition in cystic fibrosis. , 1996, Journal of hepatology.

[31]  A. Larghi,et al.  Clinical Pharmacokinetics of Therapeutic Bile Acids , 1996, Clinical pharmacokinetics.

[32]  B. Rowlands,et al.  Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. , 1996, European Journal of Gastroenterology and Hepathology.

[33]  S. Azer,et al.  Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. , 1993, Hepatology.

[34]  S. Azer,et al.  Daily determination of individual serum bile acids allows early detection of hepatic allograft dysfunction , 1993, Hepatology.

[35]  D. Russell,et al.  Bile acid biosynthesis. , 1992, Biochemistry.

[36]  D. Heuman Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. , 1989, Journal of lipid research.

[37]  K. Setchell,et al.  Serum bile acid composition in patients with cystic fibrosis. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[38]  G. Lepage,et al.  Effect of Taurine Supplements on Fat Absorption in Cystic Fibrosis , 1985, Pediatric Research.

[39]  S. Ewerth Postprandial serum concentration of individual bile acids in man. Influence of ileal resection. , 1982, Scandinavian journal of gastroenterology.

[40]  L. Swell,et al.  Bile acid metabolism in cirrhosiso. VII. Evidence for defective feedback control of bile acid synthesis , 1981, Hepatology.

[41]  G. Lepage,et al.  Relationship between bile acid malabsorption and pancreatic insufficiency in cystic fibrosis. , 1976, Gut.

[42]  K. Setchell,et al.  2 – Bile Acids and Bile Flow: New Functions of Old Molecules , 2018 .

[43]  M. Corey,et al.  Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. , 2011, Gastroenterology.

[44]  Bruno Stieger,et al.  Enterohepatic bile salt transporters in normal physiology and liver disease. , 2004, Gastroenterology.

[45]  H. Komatsu,et al.  Simultaneous determination of bile acids in rat liver tissue by high-performance liquid chromatography. , 1998, Journal of Chromatography B: Biomedical Sciences and Applications.

[46]  H. Skopnik,et al.  Taurin-Supplementierung bei Cystischer Fibrose (CF): Einfluß auf die Absorptionskinetik von Vitamin E , 1991 .

[47]  G. Heimann,et al.  [Taurine supplementation in cystic fibrosis (CF): effect on vitamin E absorption kinetics]. , 1991, Klinische Padiatrie.

[48]  D. Alvaro,et al.  Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. , 1986, Medical hypotheses.